634
+8.19%
Close of 9 Nov 2026, in JPY
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Japan Tissue Engineering Co
Its shares trade on Tokyo Stock Exchange under the ticker 7774.T. It has been listed since 21 December 2007. In the fiscal year to 31 March 2026, it reported revenue of ¥2.18bn and a net loss of ¥734.8m. At that date it held total assets of ¥5.68bn and shareholders' equity of ¥5.09bn.
Japan Tissue Engineering Co., Ltd. engages in the research, development, and manufacture of cultured biological cells and tissues. The company is headquartered in Gamagori-Shi, Aichi-Ken. The company went IPO on 2007-12-21. The firm operates through three segments. The Regenerative Medicine Product segment develops regenerative medicine products using tissue engineering, and manufactures and sells the products for medical institutions. The regenerative medicine products include autologous cultured epidermis JACE, and autologous cultured cartilage JACK. The Regenerative Medicine Outsourcing segment provides contract development and manufacturing organization (CDMO) services, contract research organization (CRO) services, consulting services, and contract manufacturing services for specific cell processed products. The Research and Development Support segment manufactures and sells human cultured tissues that apply advanced culture technology accumulated through the development of in-house products.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 21 Dec 2007
- Employees
- 215
- Website
- jpte.co.jp ↗
Leadership
Pay as last reported
- Mr. Kenichiro HataExecutive President, Chief Executive Officer, Representative Director, since 2004
- Mr. Kazuto YamadaExecutive Vice President, Director of Reliability Assurance
- Mr. Toshihiro OsukaSenior Managing Executive Officer, Director, since 2004
- Mr. Hiroaki MuraiExecutive Officer, Director of Business Administration
- Ms. Michiyo AibaExecutive Officer, Director of Pharmaceutical Affairs
- Mr. Masukazu InoieExecutive Officer
- Mr. Yukio MoriExecutive Officer, since 2006
- Mr. Masahito ObayashiExecutive Officer, since 2009
- Mr. Akinobu WakabayashiExecutive Officer, Manager of Strategic Planning Office
- Mr. Hirotsugu HigashiyamaNon-Executive Director
- Mr. Takayuki NakanoNon-Executive Director
- Mr. Yasuo KitajimaIndependent Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Japan Tissue Engineering Co Ltd operates in the Health Care sector with a focus on Biotechnology.
- The company has a product line including autologous cultured epidermis JACE and autologous cultured cartilage JACK.
- The firm's Regenerative Medicine Outsourcing segment provides CDMO and CRO services for cell processed products.
Weaknesses
- The company has only one city, Gamagori-shi, as its headquarters location.
- Japan Tissue Engineering Co Ltd has a single IPO date of December 21, 2007, indicating limited market history.
- The company employs 215 full-time employees, which may constrain operational scale.
Opportunities
- The Regenerative Medicine Product segment can expand the market for autologous cultured epidermis JACE.
- The Regenerative Medicine Outsourcing segment can leverage CDMO services for growing biotechnology demand.
- The Research and Development Support segment can utilize advanced culture technology for new tissue products.
Threats
- The company's operations are limited to Japan, restricting international market access.
- The Regenerative Medicine Product segment relies on specific products like JACE and JACK, increasing vulnerability to market shifts.
- The company's single IPO date may indicate limited financial flexibility compared to firms with multiple capital raises.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.